CN117298132B - 一种归知糖疽有效成分配方在制备治疗糖尿病肾病药物中的应用 - Google Patents
一种归知糖疽有效成分配方在制备治疗糖尿病肾病药物中的应用 Download PDFInfo
- Publication number
- CN117298132B CN117298132B CN202311623283.0A CN202311623283A CN117298132B CN 117298132 B CN117298132 B CN 117298132B CN 202311623283 A CN202311623283 A CN 202311623283A CN 117298132 B CN117298132 B CN 117298132B
- Authority
- CN
- China
- Prior art keywords
- formula
- diabetic nephropathy
- effective ingredient
- group
- beta
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000004615 ingredient Substances 0.000 title claims abstract description 40
- 239000003814 drug Substances 0.000 title claims abstract description 38
- 208000007342 Diabetic Nephropathies Diseases 0.000 title claims abstract description 30
- 208000033679 diabetic kidney disease Diseases 0.000 title claims abstract description 30
- 206010007882 Cellulitis Diseases 0.000 title description 9
- AEDDIBAIWPIIBD-ZJKJAXBQSA-N mangiferin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1C1=C(O)C=C(OC=2C(=CC(O)=C(O)C=2)C2=O)C2=C1O AEDDIBAIWPIIBD-ZJKJAXBQSA-N 0.000 claims abstract description 30
- 206010007247 Carbuncle Diseases 0.000 claims abstract description 25
- CXQWRCVTCMQVQX-LSDHHAIUSA-N (+)-taxifolin Chemical compound C1([C@@H]2[C@H](C(C3=C(O)C=C(O)C=C3O2)=O)O)=CC=C(O)C(O)=C1 CXQWRCVTCMQVQX-LSDHHAIUSA-N 0.000 claims abstract description 20
- KAZSKMJFUPEHHW-UHFFFAOYSA-N (2E)-3-[5-(1,1-dimethyl-2-propenyl)-4-hydroxy-2-methoxyphenyl]-1-(4-hdyroxyphenyl)-2-propen-1-one Natural products COC1=CC(O)=C(C(C)(C)C=C)C=C1C=CC(=O)C1=CC=C(O)C=C1 KAZSKMJFUPEHHW-UHFFFAOYSA-N 0.000 claims abstract description 15
- IQVQXVFMNOFTMU-FLIBITNWSA-N (Z)-ligustilide Chemical compound C1CC=CC2=C1C(=C/CCC)/OC2=O IQVQXVFMNOFTMU-FLIBITNWSA-N 0.000 claims abstract description 15
- QIIDATRCGITYRZ-UHFFFAOYSA-N Catalpol Natural products OCC1OC(OC2OC=CC3C(O)C(=C(CO)C23)O)C(O)C(O)C1O QIIDATRCGITYRZ-UHFFFAOYSA-N 0.000 claims abstract description 15
- 206010017711 Gangrene Diseases 0.000 claims abstract description 15
- KAZSKMJFUPEHHW-DHZHZOJOSA-N Licochalcone A Chemical compound COC1=CC(O)=C(C(C)(C)C=C)C=C1\C=C\C(=O)C1=CC=C(O)C=C1 KAZSKMJFUPEHHW-DHZHZOJOSA-N 0.000 claims abstract description 15
- IUCVKTHEUWACFB-UHFFFAOYSA-N Licochalcone A Natural products COC1=CC=C(C(C)(C)C=C)C=C1C=CC(=O)C1=CC=C(O)C=C1 IUCVKTHEUWACFB-UHFFFAOYSA-N 0.000 claims abstract description 15
- YWQSXCGKJDUYTL-UHFFFAOYSA-N Mangiferin Natural products CC(CCC=C(C)C)C1CC(C)C2C3CCC4C(C)(C)CCCC45CC35CCC12C YWQSXCGKJDUYTL-UHFFFAOYSA-N 0.000 claims abstract description 15
- SORUXVRKWOHYEO-FRUGGTEYSA-N Timosaponin b ii Chemical compound O([C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1C[C@H]2CC[C@H]3[C@@H]4C[C@@H]5OC([C@H]([C@@H]5[C@@]4(C)CC[C@@H]3[C@@]2(C)CC1)C)(O)CC[C@H](C)CO[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O SORUXVRKWOHYEO-FRUGGTEYSA-N 0.000 claims abstract description 15
- IQVQXVFMNOFTMU-DHZHZOJOSA-N Z-ligustilide Natural products C1CC=CC2=C1C(=C/CCC)\OC2=O IQVQXVFMNOFTMU-DHZHZOJOSA-N 0.000 claims abstract description 15
- UTDFQMAXCUGNJR-UHFFFAOYSA-N aucubin Natural products OCC1OC(Oc2ccoc2C3C(O)CCC3O)C(O)C(O)C1O UTDFQMAXCUGNJR-UHFFFAOYSA-N 0.000 claims abstract description 15
- RJWJHRPNHPHBRN-FKVJWERZSA-N aucubin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@H]1[C@@H]2C(CO)=C[C@@H](O)[C@@H]2C=CO1 RJWJHRPNHPHBRN-FKVJWERZSA-N 0.000 claims abstract description 15
- YBHILYKTIRIUTE-UHFFFAOYSA-N berberine Chemical compound C1=C2CC[N+]3=CC4=C(OC)C(OC)=CC=C4C=C3C2=CC2=C1OCO2 YBHILYKTIRIUTE-UHFFFAOYSA-N 0.000 claims abstract description 15
- QISXPYZVZJBNDM-UHFFFAOYSA-N berberine Natural products COc1ccc2C=C3N(Cc2c1OC)C=Cc4cc5OCOc5cc34 QISXPYZVZJBNDM-UHFFFAOYSA-N 0.000 claims abstract description 15
- 229940093265 berberine Drugs 0.000 claims abstract description 15
- 229940076810 beta sitosterol Drugs 0.000 claims abstract description 15
- LGJMUZUPVCAVPU-UHFFFAOYSA-N beta-Sitostanol Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(C)CCC(CC)C(C)C)C1(C)CC2 LGJMUZUPVCAVPU-UHFFFAOYSA-N 0.000 claims abstract description 15
- NJKOMDUNNDKEAI-UHFFFAOYSA-N beta-sitosterol Natural products CCC(CCC(C)C1CCC2(C)C3CC=C4CC(O)CCC4C3CCC12C)C(C)C NJKOMDUNNDKEAI-UHFFFAOYSA-N 0.000 claims abstract description 15
- LHDWRKICQLTVDL-PZYDOOQISA-N catalpol Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@H]1[C@@H]2[C@@]3(CO)O[C@H]3[C@@H](O)[C@@H]2C=CO1 LHDWRKICQLTVDL-PZYDOOQISA-N 0.000 claims abstract description 15
- UXSACQOOWZMGSE-UHFFFAOYSA-N catalposide Natural products OC1C(O)C(O)C(CO)OC1OC1C2C3(CO)OC3C(OC(=O)C=3C=CC(O)=CC=3)C2C=CO1 UXSACQOOWZMGSE-UHFFFAOYSA-N 0.000 claims abstract description 15
- 229940043357 mangiferin Drugs 0.000 claims abstract description 15
- LHDWRKICQLTVDL-UHFFFAOYSA-N methyl iridoid glycoside Natural products OC1C(O)C(O)C(CO)OC1OC1C2C3(CO)OC3C(O)C2C=CO1 LHDWRKICQLTVDL-UHFFFAOYSA-N 0.000 claims abstract description 15
- KZJWDPNRJALLNS-VJSFXXLFSA-N sitosterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CC[C@@H](CC)C(C)C)[C@@]1(C)CC2 KZJWDPNRJALLNS-VJSFXXLFSA-N 0.000 claims abstract description 15
- 229950005143 sitosterol Drugs 0.000 claims abstract description 15
- SORUXVRKWOHYEO-UHFFFAOYSA-N timosaponin B-II Natural products O1C(CO)C(O)C(O)C(O)C1OCC(C)CCC(C(C1C2(C)CCC3C4(C)CC5)C)(O)OC1CC2C3CCC4CC5OC1OC(CO)C(O)C(O)C1OC1OC(CO)C(O)C(O)C1O SORUXVRKWOHYEO-UHFFFAOYSA-N 0.000 claims abstract description 15
- MWDZOUNAPSSOEL-UHFFFAOYSA-N kaempferol Natural products OC1=C(C(=O)c2cc(O)cc(O)c2O1)c3ccc(O)cc3 MWDZOUNAPSSOEL-UHFFFAOYSA-N 0.000 claims abstract description 13
- IQPNAANSBPBGFQ-UHFFFAOYSA-N luteolin Chemical compound C=1C(O)=CC(O)=C(C(C=2)=O)C=1OC=2C1=CC=C(O)C(O)=C1 IQPNAANSBPBGFQ-UHFFFAOYSA-N 0.000 claims abstract description 13
- LRDGATPGVJTWLJ-UHFFFAOYSA-N luteolin Natural products OC1=CC(O)=CC(C=2OC3=CC(O)=CC(O)=C3C(=O)C=2)=C1 LRDGATPGVJTWLJ-UHFFFAOYSA-N 0.000 claims abstract description 13
- 235000009498 luteolin Nutrition 0.000 claims abstract description 13
- OVSQVDMCBVZWGM-SJWGPRHPSA-N Hyperin Natural products O[C@H]1[C@H](O)[C@@H](O)[C@@H](CO)O[C@H]1OC1=C(C=2C=C(O)C(O)=CC=2)OC2=CC(O)=CC(O)=C2C1=O OVSQVDMCBVZWGM-SJWGPRHPSA-N 0.000 claims abstract description 12
- FVQOMEDMFUMIMO-UHFFFAOYSA-N Hyperosid Natural products OC1C(O)C(O)C(CO)OC1OC1C(=O)C2=C(O)C=C(O)C=C2OC1C1=CC=C(O)C(O)=C1 FVQOMEDMFUMIMO-UHFFFAOYSA-N 0.000 claims abstract description 12
- OVSQVDMCBVZWGM-DTGCRPNFSA-N quercetin 3-O-beta-D-galactopyranoside Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1OC1=C(C=2C=C(O)C(O)=CC=2)OC2=CC(O)=CC(O)=C2C1=O OVSQVDMCBVZWGM-DTGCRPNFSA-N 0.000 claims abstract description 12
- BBFYUPYFXSSMNV-UHFFFAOYSA-N quercetin-7-o-galactoside Natural products OC1C(O)C(O)C(CO)OC1OC1=CC(O)=C2C(=O)C(O)=C(C=3C=C(O)C(O)=CC=3)OC2=C1 BBFYUPYFXSSMNV-UHFFFAOYSA-N 0.000 claims abstract description 12
- KQNGHARGJDXHKF-UHFFFAOYSA-N dihydrotamarixetin Natural products C1=C(O)C(OC)=CC=C1C1C(O)C(=O)C2=C(O)C=C(O)C=C2O1 KQNGHARGJDXHKF-UHFFFAOYSA-N 0.000 claims abstract description 10
- IIXHQGSINFQLRR-UHFFFAOYSA-N Piceatannol Natural products Oc1ccc(C=Cc2c(O)c(O)c3CCCCc3c2O)cc1O IIXHQGSINFQLRR-UHFFFAOYSA-N 0.000 claims abstract description 9
- OZWDYLLMBFLSNH-UHFFFAOYSA-N Swertisin Natural products COc1cc2OC(=CC(=O)c2c(O)c1OC3OC(CO)C(O)C(O)C3O)c4cccc(O)c4 OZWDYLLMBFLSNH-UHFFFAOYSA-N 0.000 claims abstract description 9
- CDRPUGZCRXZLFL-OWOJBTEDSA-N piceatannol Chemical compound OC1=CC(O)=CC(\C=C\C=2C=C(O)C(O)=CC=2)=C1 CDRPUGZCRXZLFL-OWOJBTEDSA-N 0.000 claims abstract description 9
- ABRULANJVVJLFI-DGHBBABESA-N swertisin Chemical compound COC1=CC=2OC(C=3C=CC(O)=CC=3)=CC(=O)C=2C(O)=C1[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O ABRULANJVVJLFI-DGHBBABESA-N 0.000 claims abstract description 9
- 241000700159 Rattus Species 0.000 claims description 30
- 210000004369 blood Anatomy 0.000 claims description 21
- 239000008280 blood Substances 0.000 claims description 21
- 210000002700 urine Anatomy 0.000 claims description 21
- DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 claims description 20
- 102000004169 proteins and genes Human genes 0.000 claims description 15
- 108090000623 proteins and genes Proteins 0.000 claims description 15
- MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 claims description 14
- 235000002226 Ranunculus ficaria Nutrition 0.000 claims description 12
- 241001530126 Scrophularia Species 0.000 claims description 12
- 210000005084 renal tissue Anatomy 0.000 claims description 12
- 229940109239 creatinine Drugs 0.000 claims description 10
- 102000049873 Smad7 Human genes 0.000 claims description 9
- 108700031279 Smad7 Proteins 0.000 claims description 9
- PNNCWTXUWKENPE-UHFFFAOYSA-N [N].NC(N)=O Chemical compound [N].NC(N)=O PNNCWTXUWKENPE-UHFFFAOYSA-N 0.000 claims description 9
- 102000004887 Transforming Growth Factor beta Human genes 0.000 claims description 8
- 108090001012 Transforming Growth Factor beta Proteins 0.000 claims description 8
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 claims description 8
- 230000003907 kidney function Effects 0.000 claims description 7
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 claims description 7
- 235000014466 Douglas bleu Nutrition 0.000 claims description 5
- 240000001416 Pseudotsuga menziesii Species 0.000 claims description 5
- 235000005386 Pseudotsuga menziesii var menziesii Nutrition 0.000 claims description 5
- 239000000284 extract Substances 0.000 claims description 5
- 229930182470 glycoside Natural products 0.000 claims description 5
- 150000002338 glycosides Chemical class 0.000 claims description 5
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 4
- 239000008103 glucose Substances 0.000 claims description 4
- 230000000291 postprandial effect Effects 0.000 claims description 4
- 102000017011 Glycated Hemoglobin A Human genes 0.000 claims description 3
- 108010014663 Glycated Hemoglobin A Proteins 0.000 claims description 3
- NQYPTLKGQJDGTI-FCVRJVSHSA-N hyperoside Natural products OC[C@H]1O[C@@H](OC2=C(Oc3cc(O)cc(O)c3[C@H]2O)c4ccc(O)c(O)c4)[C@H](O)[C@@H](O)[C@H]1O NQYPTLKGQJDGTI-FCVRJVSHSA-N 0.000 claims description 3
- 210000002966 serum Anatomy 0.000 claims description 3
- HEYZWPRKKUGDCR-QBXMEVCASA-N Swertiamarin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@H]1[C@H](C=C)[C@]2(O)CCOC(=O)C2=CO1 HEYZWPRKKUGDCR-QBXMEVCASA-N 0.000 claims description 2
- HEYZWPRKKUGDCR-WRMJXEAJSA-N Swertiamarin Natural products O([C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1)[C@H]1[C@@H](C=C)[C@@]2(O)C(C(=O)OCC2)=CO1 HEYZWPRKKUGDCR-WRMJXEAJSA-N 0.000 claims description 2
- 241000213006 Angelica dahurica Species 0.000 claims 3
- 230000000694 effects Effects 0.000 abstract description 19
- 229940079593 drug Drugs 0.000 abstract description 8
- 210000003734 kidney Anatomy 0.000 description 13
- 208000024891 symptom Diseases 0.000 description 12
- 206010012601 diabetes mellitus Diseases 0.000 description 11
- 239000002245 particle Substances 0.000 description 11
- 239000000470 constituent Substances 0.000 description 10
- 230000002829 reductive effect Effects 0.000 description 10
- 230000007812 deficiency Effects 0.000 description 8
- 238000002347 injection Methods 0.000 description 7
- 239000007924 injection Substances 0.000 description 7
- 238000011160 research Methods 0.000 description 7
- 238000012360 testing method Methods 0.000 description 7
- 238000009472 formulation Methods 0.000 description 6
- YCPOHTHPUREGFM-UHFFFAOYSA-N irbesartan Chemical compound O=C1N(CC=2C=CC(=CC=2)C=2C(=CC=CC=2)C=2[N]N=NN=2)C(CCCC)=NC21CCCC2 YCPOHTHPUREGFM-UHFFFAOYSA-N 0.000 description 6
- 239000000203 mixture Substances 0.000 description 6
- 208000011580 syndromic disease Diseases 0.000 description 6
- 206010030113 Oedema Diseases 0.000 description 5
- -1 cryptotaquone Chemical compound 0.000 description 5
- 238000000034 method Methods 0.000 description 5
- 208000035484 Cellulite Diseases 0.000 description 4
- 206010049752 Peau d'orange Diseases 0.000 description 4
- 230000036232 cellulite Effects 0.000 description 4
- 239000008187 granular material Substances 0.000 description 4
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 4
- 230000007246 mechanism Effects 0.000 description 4
- 230000001225 therapeutic effect Effects 0.000 description 4
- DSCFFEYYQKSRSV-FEPQRWDDSA-N (-)-Quebrachitol Natural products COC1[C@@H](O)[C@@H](O)C(O)[C@H](O)[C@H]1O DSCFFEYYQKSRSV-FEPQRWDDSA-N 0.000 description 3
- DSCFFEYYQKSRSV-GWJPIIGYSA-N 1D-5-O-methyl-myo-inositol Chemical compound CO[C@@H]1[C@@H](O)[C@H](O)[C@H](O)[C@H](O)[C@H]1O DSCFFEYYQKSRSV-GWJPIIGYSA-N 0.000 description 3
- DSCFFEYYQKSRSV-UHFFFAOYSA-N 1L-O1-methyl-muco-inositol Natural products COC1C(O)C(O)C(O)C(O)C1O DSCFFEYYQKSRSV-UHFFFAOYSA-N 0.000 description 3
- 239000009636 Huang Qi Substances 0.000 description 3
- 102000015271 Intercellular Adhesion Molecule-1 Human genes 0.000 description 3
- 108010064593 Intercellular Adhesion Molecule-1 Proteins 0.000 description 3
- 208000001647 Renal Insufficiency Diseases 0.000 description 3
- 240000004980 Rheum officinale Species 0.000 description 3
- 235000008081 Rheum officinale Nutrition 0.000 description 3
- 210000000805 cytoplasm Anatomy 0.000 description 3
- 238000003745 diagnosis Methods 0.000 description 3
- 230000004069 differentiation Effects 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- BTXNYTINYBABQR-UHFFFAOYSA-N hypericin Chemical compound C12=C(O)C=C(O)C(C(C=3C(O)=CC(C)=C4C=33)=O)=C2C3=C2C3=C4C(C)=CC(O)=C3C(=O)C3=C(O)C=C(O)C1=C32 BTXNYTINYBABQR-UHFFFAOYSA-N 0.000 description 3
- 229940005608 hypericin Drugs 0.000 description 3
- PHOKTTKFQUYZPI-UHFFFAOYSA-N hypericin Natural products Cc1cc(O)c2c3C(=O)C(=Cc4c(O)c5c(O)cc(O)c6c7C(=O)C(=Cc8c(C)c1c2c(c78)c(c34)c56)O)O PHOKTTKFQUYZPI-UHFFFAOYSA-N 0.000 description 3
- 201000006370 kidney failure Diseases 0.000 description 3
- 210000004185 liver Anatomy 0.000 description 3
- 210000003584 mesangial cell Anatomy 0.000 description 3
- 201000001474 proteinuria Diseases 0.000 description 3
- SSKVDVBQSWQEGJ-UHFFFAOYSA-N pseudohypericin Natural products C12=C(O)C=C(O)C(C(C=3C(O)=CC(O)=C4C=33)=O)=C2C3=C2C3=C4C(C)=CC(O)=C3C(=O)C3=C(O)C=C(O)C1=C32 SSKVDVBQSWQEGJ-UHFFFAOYSA-N 0.000 description 3
- 230000001105 regulatory effect Effects 0.000 description 3
- 210000000582 semen Anatomy 0.000 description 3
- 210000000952 spleen Anatomy 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- UUUHXMGGBIUAPW-UHFFFAOYSA-N 1-[1-[2-[[5-amino-2-[[1-[5-(diaminomethylideneamino)-2-[[1-[3-(1h-indol-3-yl)-2-[(5-oxopyrrolidine-2-carbonyl)amino]propanoyl]pyrrolidine-2-carbonyl]amino]pentanoyl]pyrrolidine-2-carbonyl]amino]-5-oxopentanoyl]amino]-3-methylpentanoyl]pyrrolidine-2-carbon Chemical compound C1CCC(C(=O)N2C(CCC2)C(O)=O)N1C(=O)C(C(C)CC)NC(=O)C(CCC(N)=O)NC(=O)C1CCCN1C(=O)C(CCCN=C(N)N)NC(=O)C1CCCN1C(=O)C(CC=1C2=CC=CC=C2NC=1)NC(=O)C1CCC(=O)N1 UUUHXMGGBIUAPW-UHFFFAOYSA-N 0.000 description 2
- 241001061264 Astragalus Species 0.000 description 2
- 239000002947 C09CA04 - Irbesartan Substances 0.000 description 2
- 102000008186 Collagen Human genes 0.000 description 2
- 108010035532 Collagen Proteins 0.000 description 2
- 241000759833 Cornus officinalis Species 0.000 description 2
- 235000002722 Dioscorea batatas Nutrition 0.000 description 2
- 235000006536 Dioscorea esculenta Nutrition 0.000 description 2
- 240000001811 Dioscorea oppositifolia Species 0.000 description 2
- 235000003416 Dioscorea oppositifolia Nutrition 0.000 description 2
- 241000792859 Enema Species 0.000 description 2
- 102000003745 Hepatocyte Growth Factor Human genes 0.000 description 2
- 108090000100 Hepatocyte Growth Factor Proteins 0.000 description 2
- 102000004877 Insulin Human genes 0.000 description 2
- 108090001061 Insulin Proteins 0.000 description 2
- 206010024642 Listless Diseases 0.000 description 2
- 240000002948 Ophiopogon intermedius Species 0.000 description 2
- 244000131316 Panax pseudoginseng Species 0.000 description 2
- 102000004270 Peptidyl-Dipeptidase A Human genes 0.000 description 2
- 108090000882 Peptidyl-Dipeptidase A Proteins 0.000 description 2
- 235000006533 astragalus Nutrition 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 229920001436 collagen Polymers 0.000 description 2
- 238000004040 coloring Methods 0.000 description 2
- 230000001934 delay Effects 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 239000007920 enema Substances 0.000 description 2
- 229940095399 enema Drugs 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 239000000835 fiber Substances 0.000 description 2
- 239000008862 fructus schizandrae, radix ginseng, radix ophiopogonis drug combination Substances 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 210000004969 inflammatory cell Anatomy 0.000 description 2
- 229940125396 insulin Drugs 0.000 description 2
- 229960002198 irbesartan Drugs 0.000 description 2
- 208000017169 kidney disease Diseases 0.000 description 2
- 208000017971 listlessness Diseases 0.000 description 2
- 230000014759 maintenance of location Effects 0.000 description 2
- 201000008383 nephritis Diseases 0.000 description 2
- 230000036542 oxidative stress Effects 0.000 description 2
- 230000008506 pathogenesis Effects 0.000 description 2
- 230000008054 signal transmission Effects 0.000 description 2
- 238000007619 statistical method Methods 0.000 description 2
- 210000004233 talus Anatomy 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 210000004926 tubular epithelial cell Anatomy 0.000 description 2
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 1
- 206010000060 Abdominal distension Diseases 0.000 description 1
- 241000173529 Aconitum napellus Species 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 241000132012 Atractylodes Species 0.000 description 1
- 208000037157 Azotemia Diseases 0.000 description 1
- 102000004506 Blood Proteins Human genes 0.000 description 1
- 108010017384 Blood Proteins Proteins 0.000 description 1
- 206010006895 Cachexia Diseases 0.000 description 1
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 1
- 208000002177 Cataract Diseases 0.000 description 1
- 244000035851 Chrysanthemum leucanthemum Species 0.000 description 1
- 235000008495 Chrysanthemum leucanthemum Nutrition 0.000 description 1
- 244000037364 Cinnamomum aromaticum Species 0.000 description 1
- 235000014489 Cinnamomum aromaticum Nutrition 0.000 description 1
- 241000756943 Codonopsis Species 0.000 description 1
- 241000209020 Cornus Species 0.000 description 1
- 208000002249 Diabetes Complications Diseases 0.000 description 1
- 244000268590 Euryale ferox Species 0.000 description 1
- 235000006487 Euryale ferox Nutrition 0.000 description 1
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 1
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 1
- 239000009429 Ginkgo biloba extract Substances 0.000 description 1
- 235000017309 Hypericum perforatum Nutrition 0.000 description 1
- 244000141009 Hypericum perforatum Species 0.000 description 1
- 208000031226 Hyperlipidaemia Diseases 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 206010020880 Hypertrophy Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 241000112528 Ligusticum striatum Species 0.000 description 1
- 239000009220 Liuwei Dihuang Decoction Substances 0.000 description 1
- 244000241838 Lycium barbarum Species 0.000 description 1
- 235000015459 Lycium barbarum Nutrition 0.000 description 1
- 235000015468 Lycium chinense Nutrition 0.000 description 1
- 241001673966 Magnolia officinalis Species 0.000 description 1
- 240000002624 Mespilus germanica Species 0.000 description 1
- 235000017784 Mespilus germanica Nutrition 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 206010027525 Microalbuminuria Diseases 0.000 description 1
- 235000000560 Mimusops elengi Nutrition 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- 235000002789 Panax ginseng Nutrition 0.000 description 1
- 235000003181 Panax pseudoginseng Nutrition 0.000 description 1
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 description 1
- 235000003140 Panax quinquefolius Nutrition 0.000 description 1
- 208000004880 Polyuria Diseases 0.000 description 1
- 241001619461 Poria <basidiomycete fungus> Species 0.000 description 1
- 244000046146 Pueraria lobata Species 0.000 description 1
- 235000010575 Pueraria lobata Nutrition 0.000 description 1
- 241000405414 Rehmannia Species 0.000 description 1
- 241000219061 Rheum Species 0.000 description 1
- 235000009411 Rheum rhabarbarum Nutrition 0.000 description 1
- 235000017276 Salvia Nutrition 0.000 description 1
- 240000007164 Salvia officinalis Species 0.000 description 1
- ZSJLQEPLLKMAKR-UHFFFAOYSA-N Streptozotocin Natural products O=NN(C)C(=O)NC1C(O)OC(CO)C(O)C1O ZSJLQEPLLKMAKR-UHFFFAOYSA-N 0.000 description 1
- VSJGJMKGNMDJCI-ZASXJUAOSA-N Sweroside Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@H]1[C@H](C=C)[C@H](CCOC2=O)C2=CO1 VSJGJMKGNMDJCI-ZASXJUAOSA-N 0.000 description 1
- 240000001949 Taraxacum officinale Species 0.000 description 1
- 235000005187 Taraxacum officinale ssp. officinale Nutrition 0.000 description 1
- 241000830536 Tripterygium wilfordii Species 0.000 description 1
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 1
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- 235000007837 Vangueria infausta Nutrition 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- 208000031975 Yang Deficiency Diseases 0.000 description 1
- 208000031971 Yin Deficiency Diseases 0.000 description 1
- 229940023019 aconite Drugs 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 210000000702 aorta abdominal Anatomy 0.000 description 1
- 230000036528 appetite Effects 0.000 description 1
- 235000019789 appetite Nutrition 0.000 description 1
- 229940107666 astragalus root Drugs 0.000 description 1
- 229960003619 benazepril hydrochloride Drugs 0.000 description 1
- VPSRQEHTHIMDQM-FKLPMGAJSA-N benazepril hydrochloride Chemical compound Cl.C([C@@H](C(=O)OCC)N[C@@H]1C(N(CC(O)=O)C2=CC=CC=C2CC1)=O)CC1=CC=CC=C1 VPSRQEHTHIMDQM-FKLPMGAJSA-N 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 238000000546 chi-square test Methods 0.000 description 1
- RNFNDJAIBTYOQL-UHFFFAOYSA-N chloral hydrate Chemical compound OC(O)C(Cl)(Cl)Cl RNFNDJAIBTYOQL-UHFFFAOYSA-N 0.000 description 1
- 229960002327 chloral hydrate Drugs 0.000 description 1
- 208000020832 chronic kidney disease Diseases 0.000 description 1
- 230000004087 circulation Effects 0.000 description 1
- 230000007012 clinical effect Effects 0.000 description 1
- 230000001447 compensatory effect Effects 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- NKLPQNGYXWVELD-UHFFFAOYSA-M coomassie brilliant blue Chemical compound [Na+].C1=CC(OCC)=CC=C1NC1=CC=C(C(=C2C=CC(C=C2)=[N+](CC)CC=2C=C(C=CC=2)S([O-])(=O)=O)C=2C=CC(=CC=2)N(CC)CC=2C=C(C=CC=2)S([O-])(=O)=O)C=C1 NKLPQNGYXWVELD-UHFFFAOYSA-M 0.000 description 1
- 230000006735 deficit Effects 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000000502 dialysis Methods 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 230000035619 diuresis Effects 0.000 description 1
- 230000000857 drug effect Effects 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 208000026500 emaciation Diseases 0.000 description 1
- 208000028208 end stage renal disease Diseases 0.000 description 1
- 201000000523 end stage renal failure Diseases 0.000 description 1
- 210000002744 extracellular matrix Anatomy 0.000 description 1
- 230000004438 eyesight Effects 0.000 description 1
- 239000006260 foam Substances 0.000 description 1
- 238000003304 gavage Methods 0.000 description 1
- 235000008434 ginseng Nutrition 0.000 description 1
- 230000001434 glomerular Effects 0.000 description 1
- 210000000585 glomerular basement membrane Anatomy 0.000 description 1
- 206010061989 glomerulosclerosis Diseases 0.000 description 1
- 230000036252 glycation Effects 0.000 description 1
- 238000007489 histopathology method Methods 0.000 description 1
- 206010020718 hyperplasia Diseases 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 238000013115 immunohistochemical detection Methods 0.000 description 1
- 230000002055 immunohistochemical effect Effects 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 238000010150 least significant difference test Methods 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 239000008876 liujunzi Substances 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 230000006996 mental state Effects 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000004796 pathophysiological change Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 210000000557 podocyte Anatomy 0.000 description 1
- 206010036067 polydipsia Diseases 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 238000002731 protein assay Methods 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 230000008327 renal blood flow Effects 0.000 description 1
- 238000009256 replacement therapy Methods 0.000 description 1
- JUVIOZPCNVVQFO-HBGVWJBISA-N rotenone Chemical compound O([C@H](CC1=C2O3)C(C)=C)C1=CC=C2C(=O)[C@@H]1[C@H]3COC2=C1C=C(OC)C(OC)=C2 JUVIOZPCNVVQFO-HBGVWJBISA-N 0.000 description 1
- JUVIOZPCNVVQFO-UHFFFAOYSA-N rotenone Natural products O1C2=C3CC(C(C)=C)OC3=CC=C2C(=O)C2C1COC1=C2C=C(OC)C(OC)=C1 JUVIOZPCNVVQFO-UHFFFAOYSA-N 0.000 description 1
- KFQYTPMOWPVWEJ-INIZCTEOSA-N rotigotine Chemical compound CCCN([C@@H]1CC2=CC=CC(O)=C2CC1)CCC1=CC=CS1 KFQYTPMOWPVWEJ-INIZCTEOSA-N 0.000 description 1
- 229960003179 rotigotine Drugs 0.000 description 1
- 239000009874 shenqi Substances 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- ZSJLQEPLLKMAKR-GKHCUFPYSA-N streptozocin Chemical compound O=NN(C)C(=O)N[C@H]1[C@@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O ZSJLQEPLLKMAKR-GKHCUFPYSA-N 0.000 description 1
- 229960001052 streptozocin Drugs 0.000 description 1
- 230000001502 supplementing effect Effects 0.000 description 1
- 208000032598 susceptibility microvascular complications of diabetes Diseases 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- VSJGJMKGNMDJCI-QXSNVGMTSA-N sweroside Natural products OC[C@H]1O[C@H](O[C@@H]2OC=C3[C@@H](CCOC3=O)[C@H]2C=C)[C@H](O)[C@@H](O)[C@@H]1O VSJGJMKGNMDJCI-QXSNVGMTSA-N 0.000 description 1
- 238000002636 symptomatic treatment Methods 0.000 description 1
- 238000012353 t test Methods 0.000 description 1
- 201000005665 thrombophilia Diseases 0.000 description 1
- 235000015398 thunder god vine Nutrition 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 230000000451 tissue damage Effects 0.000 description 1
- 231100000827 tissue damage Toxicity 0.000 description 1
- 229940126680 traditional chinese medicines Drugs 0.000 description 1
- 230000001131 transforming effect Effects 0.000 description 1
- 231100000397 ulcer Toxicity 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/12—Ketones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
- A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Urology & Nephrology (AREA)
- Molecular Biology (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
本发明属于医药领域，特别涉及一种归知糖疽有效成分配方在制备治疗糖尿病肾病药物中的应用。所述归知糖疽有效成分配方包括以下成分：藁本内酯、β‑谷甾醇、花旗松素、木犀草素、小檗碱、甘草查耳酮A、柳杉酚、知母皂苷B‑II、芒果苷、獐牙菜苷、金丝桃苷、梓醇、桃叶珊瑚苷、玄参苷。利用该配方制备的药物对糖尿病肾病具有优异的治疗效果。
Description
技术领域
本发明属于医药领域，特别涉及一种归知糖疽有效成分配方在制备治疗糖尿病肾病药物中的应用。
背景技术
糖尿病肾病是糖尿病最主要的微血管并发症之一，而它所致的终末期肾病己逐渐成为导致肾功衰竭的主要原因。目前，针对糖尿病肾病的治疗，西医范围局限，基本以降糖、调脂或配合应用ACEI、ARB类药物对症治疗，但结果收效不佳。而中医药在治疗本病上，发挥特色，辨证施治，随症加减，尤其在改善糖尿病肾病早、中期临床症状和病变，疗效更为显著，可有效预防、延缓糖尿病肾病的发生、发展。
糖尿病肾病分为早、中、晚3期。早期多以肺胃热盛，耗伤气阴为主，方以参芪地黄汤加减；中期分阳虚水停、阴虚水停、湿热内蕴、气虚水停、气滞水停、血瘀水停6型；晚期分虚损和关格2期，治方以补虚及清湿热为法。李小娟则以有无水肿将DN分为两型。李氏认为，无水肿型是糖尿病的早期证型，常用益气养阴、滋补肝肾之法，方以生脉散合六味地黄汤加减；有水肿型是DN晚期证型，常予健脾益肾、益气行水之法，方选六君子汤合六味地黄汤加减。刘宝厚则根据DN发病不同阶段的特点，分为4期。(1)早期：相当于Mogensen分期的Ⅰ、Ⅱ期，即DM初期和隐匿期，证型以肝肾阴虚为主，治宜滋养肝肾、清热明目，药用山药、枸杞子、生地黄、山茱萸肉、玄参、麦冬、野菊花等；(2)临床出现持续的微量白蛋白尿时，相当于Mogensen分期的Ⅲ期，即早期肾病期，证型以气阴两虚为主，治宜益气养阴，药用太子参、黄芪、山茱萸、生地黄、山药、麦冬、葛根等；(3)临床出现蛋白尿、浮肿、肾功能减退时，相当于Mogensen分期的Ⅳ期，即临床肾病期，证型以脾肾气（阳）虚证为主，治以培补脾肾、益气活血，药用党参、黄芪、黄精、山茱萸肉、生地黄、车前子、桂枝等；(4)晚期DN，相当于Mogensen分期的Ⅴ期，即肾衰竭期，则需做透析予替代治疗。
在治疗方面，王秀芬等以补阳还五汤加减治疗早期DN40例，明显降低蛋白尿，并通过动物实验对其作用机理予以探讨。孙元荣对64例脾肾两虚，瘀血阻络证型的DN期患者，予培土滋水汤（人参15ｇ，生黄芪30ｇ，山药30ｇ，桑寄生30ｇ，生地黄15ｇ，茯苓30ｇ，白术20ｇ，金樱子、芡实各20ｇ，益母草、丹参、赤小豆各30ｇ，砂仁6ｇ，陈皮10ｇ，泽泻30ｇ，苍术10ｇ）治疗，1剂/天，疗程90天，治疗后总有效率达90.63％。北京中医药大学东直门医院自拟中药汤剂（生黄芪50ｇ，白术10ｇ，川芎20ｇ，三七粉3ｇ，知母5ｇ，大黄15ｇ，枸杞子10ｇ，丹参20ｇ，生地黄10ｇ，贯叶金丝桃30ｇ，加入500ml，水煎至100ml，早晚分2次服，每日1剂）联合胰岛素治疗64例早期DN患者，将其随机分为两组，对照组予常规治疗，治疗组在对照组基础上加用自拟中药汤剂，4周为1个疗程，3个疗程后观察临床效果。结果显示，治疗组治疗后空腹血糖、餐后2h血糖、糖化血红蛋白、血肌酐、尿微量蛋白以及尿蛋白水平均明显低于对照组（P＜0.05），治疗组临床总有效率为90.63％，明显高于对照组之75.00％（P＜0.05）。
在其它疗法方面，辛爽清应用肾炎康复片治疗DN22例，对照组予厄贝沙坦治疗，结果显示治疗后肾炎康复片组UMA及UAER与厄贝沙坦组比较明显降低，差异有统计学意义（P＜0.05），总有效率达81.81％，明显优于厄贝沙坦组。司廷林等用黄芪注射液治疗DN45例，并设对照组，结果显示，经黄芪注射液治疗后患者血清总蛋白升高，尿素氮、血肌酐及尿白蛋白明显降低，并且优于对照组。王凌芬应用益气养阴，调和气血之参麦注射液临床观察43例，认为红参和麦冬治疗早期DN疗效肯定。魏何泽使用中药［生大黄（后下）、附子（先煎）、煅牡蛎、蒲公英、黄芪、厚朴］保留灌肠治疗DN30例，通过观察治疗前后肾功能的变化，发现患者血肌酐、尿素氮较治疗前明显降低，说明中药保留灌肠对DN氮质血症疗效肯定。
在糖尿病肾病的发病过程中，血清晚期糖化终末产物（AGEs）沉积于组织后诱发氧化应激，可引起一系列病理生理学变化，被认为是导致糖尿病组织损伤的重要原因。GaoQ认为雷公藤钩F（TwHF）具有抗氧化应激、抗炎、免疫抑制剂和保护足突细胞的作用，也可改善高脂血症和肥胖，达到保护肾脏的作用。许成群等认为大黄能抑制系膜细胞及肾小管上皮细胞增生，减轻代偿性肥大，延缓肾小球硬化，改善肾衰竭患者的高凝、高黏状态，改善肾血流量，保护残余肾功能，减少蛋白尿，延缓DN的发展。DN运用大黄辨证治疗，能提高临床疗效。孙健等研究表明银杏叶提取物可以抑制血管紧张素转化酶（ACE），上调肝细胞生长因子（HGF）/c-met的表达，下调转化生长因子～1的表达，减轻肾小球系膜区增生，改善肾功能。田风胜等观察到大黄能抑制糖尿病大鼠肾脏细胞间黏附分子～1（ICAM-1）及血管间黏附分子～1表达，起到保护糖尿病大鼠肾脏的作用。张小卿等研究提示益气解毒活络中药复方可能是通过降低MCP-1mRNA和TNF-αmRNA的高表达来实现防治DN发生发展的药理机制。
总的说来，中医在治疗糖尿病肾病方面，当代医家积累了丰富经验，临床研究取得了很大进展，但目前归知糖疽有效成分配方在制备治疗糖尿病肾病药物中的应用尚未见相关研究。
发明内容
针对现有技术中存在的问题，本发明提供一种归知糖疽有效成分配方在制备治疗糖尿病肾病药物中的应用。
本发明是通过如下技术方案实现的：
本发明的第一个目的在于提供一种归知糖疽有效成分配方在制备治疗糖尿病肾病药物中的应用。
优选的，所述归知糖疽有效成分配方包括以下成分：藁本内酯、β-谷甾醇、花旗松素、木犀草素、小檗碱、甘草查耳酮A、柳杉酚、知母皂苷B-II、芒果苷、獐牙菜苷、金丝桃苷、梓醇、桃叶珊瑚苷、玄参苷。
优选的，所述归知糖疽有效成分配方的各个成分的质量比为藁本内酯∶β-谷甾醇∶花旗松素∶木犀草素∶小檗碱∶甘草查耳酮A∶柳杉酚∶知母皂苷B-II∶芒果苷∶獐牙菜苷∶金丝桃苷∶梓醇∶桃叶珊瑚苷∶玄参苷为(2.5-3.0)：(2.1-4.7)：(3.5-6.4)：(1.8-3.2)：(1.6-2.6)：(0.6-1.7)：(2.5-3.6)：(2.2-5.2)：(2.8-5.2)：(0.6-2.1)：(1.4-4.4)：(0.3-1.2)：(1.0-2.5)：(0.9-2.7)。
优选的，所述各个成分的质量比为藁本内酯∶β-谷甾醇∶花旗松素∶木犀草素∶小檗碱∶甘草查耳酮A∶柳杉酚∶知母皂苷B-II∶芒果苷∶獐牙菜苷∶金丝桃苷∶梓醇∶桃叶珊瑚苷∶玄参苷为2.75∶3.4∶4.95∶2.5∶2.1∶1.25∶3.05∶3.65∶4.2∶1.25∶3.0∶0.75∶1.65∶1.8。
优选的，所述归知糖疽有效成分配方能明显减少DN大鼠24h尿蛋白含量，降低BUN、Scr、TG含量，提高NO的含量，改善肾功能。
优选的，所述归知糖疽有效成分配方可以减少肾组织中TGF-β1蛋白表达，增加Smad7蛋白表达。
优选的，所述归知糖疽有效成分配方能明显降低24hUpro、UAER、FBG、2hPG、HbA1c。
本发明的第二个目的在于提供一种治疗糖尿病肾病的药物，所述药物包括归知糖疽有效成分配方，所述有效成分配方包括以下成分：藁本内酯、β-谷甾醇、花旗松素、木犀草素、小檗碱、甘草查耳酮A、柳杉酚、知母皂苷B-II、芒果苷、獐牙菜苷、金丝桃苷、梓醇、桃叶珊瑚苷、玄参苷，所述各个成分的质量比为藁本内酯∶β-谷甾醇∶花旗松素∶木犀草素∶小檗碱∶甘草查耳酮A∶柳杉酚∶知母皂苷B-II∶芒果苷∶獐牙菜苷∶金丝桃苷∶梓醇∶桃叶珊瑚苷∶玄参苷为2.75∶3.4∶4.95∶2.5∶2.1∶1.25∶3.05∶3.65∶4.2∶1.25∶3.0∶0.75∶1.65∶1.8。
本发明的有益技术效果：
本发明提供了一种归知糖疽有效成分配方，以及利用该配方制备的药物，所述药物对糖尿病肾病具有优异的治疗效果。
具体实施方式
下面将结合实施例对本发明的技术方案进行清楚、完整地描述，显然，所描述的实施例是本发明一部分实施例，而不是全部的实施例。基于本发明中的实施例，本领域普通技术人员在没有做出创造性劳动前提下所获得的所有其他实施例，都属于本发明保护的范围。
根据本发明的一个方面，一种归知糖疽有效成分配方在制备治疗糖尿病肾病药物中的应用。
所述归知糖疽有效成分配方包括藁本内酯、β-谷甾醇、花旗松素、木犀草素、小檗碱、甘草查耳酮A、柳杉酚、知母皂苷B-II、芒果苷、獐牙菜苷、金丝桃苷、梓醇、桃叶珊瑚苷、玄参苷。
本发明提供的归知糖疽有效成分配方在制备治疗糖尿病肾病药物中的应用，所述归知糖疽有效成分配方包括藁本内酯、β-谷甾醇、花旗松素、木犀草素、小檗碱、甘草查耳酮A、柳杉酚、知母皂苷B-II、芒果苷、獐牙菜苷、金丝桃苷、梓醇、桃叶珊瑚苷、玄参苷。本发明通过实验研究发现，归知糖疽有效成分对糖尿病肾病具有良好的治疗效果。
实施例1
归知糖疽有效成分配方
归知糖疽有效成分配方的质量比例为2.5∶2.1∶3.5∶1.9∶1.6∶0.6∶2.5∶2.2∶2.8∶0.6∶1.4∶0.3∶1.0∶0.9的藁本内酯∶β-谷甾醇∶花旗松素∶木犀草素∶小檗碱∶甘草查耳酮A∶柳杉酚∶知母皂苷B-II∶芒果苷∶獐牙菜苷∶金丝桃苷∶梓醇∶桃叶珊瑚苷∶玄参苷。
实施例2
归知糖疽有效成分配方
归知糖疽有效成分配方的质量比例为3.0∶4.7∶6.4∶3.2∶2.6∶1.7∶3.6∶5.2∶5.2∶2.1∶4.4∶1.2∶2.5∶2.7的藁本内酯∶β-谷甾醇∶花旗松素∶木犀草素∶小檗碱∶甘草查耳酮A∶柳杉酚∶知母皂苷B-II∶芒果苷∶獐牙菜苷∶金丝桃苷∶梓醇∶桃叶珊瑚苷∶玄参苷。
实施例3
归知糖疽有效成分配方
归知糖疽有效成分配方的质量比例为2.75∶3.4∶4.95∶2.5∶2.1∶1.25∶3.05∶3.65∶4.2∶1.25∶3.0∶0.75∶1.65∶1.8的藁本内酯∶β-谷甾醇∶花旗松素∶木犀草素∶小檗碱∶甘草查耳酮A∶柳杉酚∶知母皂苷B-II∶芒果苷∶獐牙菜苷∶金丝桃苷∶梓醇∶桃叶珊瑚苷∶玄参苷。
实验例4
归知糖疽有效成分配方治疗糖尿病肾病大鼠试验
药品和试剂：归知糖疽有效成分配方(自制)；厄贝沙坦片；链脲佐菌素，美国Sigma公司；免疫组化试剂，Abcam公司。
1、模型建立
健康SPF级SD雄性大鼠，体质量(200±20)g，适应性喂养1周，按体质量随机分成正常组(A组，10只)及造模组(30只)。依据预实验结果，30只大鼠腹腔注射STZ45mg/kg，72h后测血糖和尿糖，血糖≥16.7mmol/L、尿糖“++++”以上者为造模成功，并按大鼠体质量随机分为模型组(B组，10只)、厄贝沙坦组(C组，17.5mg/kg，10只)、归知糖疽有效成分配方组(D组，E组，F组，G组，H组，均为0.6g/kg)各10只。各组大鼠均灌胃给药，正常组灌胃等体积的生理盐水，1次/d，各组共连续观察12周。
表1 归知糖疽有效成分配方组中含量表
2、观察指标
（1）一般状态观察：大鼠的精神状态、体质量、饮食、皮毛及活动情况等。
（2）24h尿蛋白测定：各组大鼠在治疗第12周用代谢笼收集大鼠24h尿液，考马斯亮蓝法检测24h尿蛋白。
（3）血液生化指标的检测：大鼠测24h尿蛋白后，予水合氯醛4mL/kg腹腔麻醉，腹主动脉采血5mL，检测血尿素氮(BUN)、血清肌酐(Scr)、甘油三酯(TG)、一氧化氮(NO)的含量。
（4）肾组织病理学分析：12周后取大鼠肾组织，无菌摘取肾脏，1/4肾组织常规固定、石蜡包埋、切片，进行HE染色。
（5）免疫组化检测：肾组织TGF-β1和Smad7蛋白表达采用SP法及用Leica显微镜拍照，400倍镜下采集图像，利用mageProplus6.0软件测量结果，取其平均值，相对阳性面积=阳性染色面积/视野大小×100%。
3、统计学方法
实验结果用表示，以SPSS19．0软件分析，组间差异采用LSD检验方法，以P<0.05为显著性差异的标准。
4、结果
（1）大鼠一般状态：
模型组大鼠出现精神萎靡，活动迟缓、消瘦、多饮、多尿等，第7周时出现溃疡、白内障等糖尿病并发症;归知糖疽有效成分配方组以上症状明显得到改善。
（2）归知糖疽有效成分配方对DN大鼠24h尿蛋白及血生化指标的影响
治疗12周后，各治疗组(B、C、D组)24h尿蛋白均较正常组(A组)有明显增加(P<0.01)。与正常组比较，模型组(B组)大鼠血清BUN、Scr、TG含量显著升高(P<0.01)，NO含量明显降低(P<0.01)；与模型组比较，厄贝沙坦组(C组)、归知糖疽有效成分配方组(D组)BUN、Scr、TG含量显著性降低(P<0.01)，NO的含量显著性升高(P<0.01)，详见表2。
表2 归知糖疽有效成分配方对DN大鼠24h尿蛋白定量及BUN、Scr、TG、NO含量的影响
注:与正常组相比，1)P<0.01；与模型组相比，2)P<0.01。
（3）归知糖疽有效成分配方对DN大鼠肾组织病理形态的影响
在400倍光镜下，B组大鼠肾组织肾小球系膜细胞中度增生，细胞外基质显著增多，肾小管上皮细胞空泡样变，肾间质大量炎细胞浸润，肾小球大量胶原纤维，系膜基质增宽，肾小球基底膜增厚。而归知糖疽有效成分配方组肾小球系膜细胞轻度增生，肾间质少量炎性细胞浸润、少量的胶原纤维。
（4）归知糖疽有效成分配方对DN大鼠肾组织中TGF-β1蛋白的影响
在A组DN大鼠肾组织肾小球固有细胞浆内可见TGF-β1蛋白表达的阳性颗粒，着色较浅，有少量棕黄色颗粒；B组则呈强阳性表达，有大量棕黄色颗粒，与A组有明显差异(P<0.01)；C组及D组可见有较少量的棕黄色颗粒，与B组有明显差异(P<0.05)，说明DN大鼠肾脏组织TGF-β1蛋白表达增强，各治疗组明显减少了TGF-β1在上述部位的表达，同时D组结果与E组，F组，G组，H组结果相比有极显著差异，见表3。
表3 归知糖疽有效成分配方对DN大鼠TGF-β1及Smad7蛋白表达水平的影响
注:与正常组相比，1)P<0.01;与模型组相比，2)P<0.05。
（5）归知糖疽有效成分配方对DN大鼠肾组织中Smad7蛋白的影响
在A组肾脏固有细胞浆内可见Smad7蛋白表达的阳性颗粒，着色较深，有大量棕黄色颗粒；B组大鼠Smad7蛋白的阳性颗粒明显减少，有少量棕黄色颗粒，与A组有明显差异(P<0.01)；C组及D组细胞浆内可见较多的棕黄色颗粒，与B组有明显差异(P<0.05)，这也说明DN大鼠肾组织中Smad7蛋白表达减少，各治疗组大鼠均较模型组有不同程度的上调Smad7蛋白表达。同时D组结果与E组，F组，G组，H组结果相比有极显著差异，见表3。
小结：本实验从整体药效和信号传导通路角度研究了归知糖疽有效成分配方对DN大鼠肾脏保护作用的机制，实验结果显示，归知糖疽有效成分配方能明显减少DN大鼠24h尿蛋白含量，显著改善肾功能，其机制可能与抑制TGF-β1/Smad信号转导通路的激活有关。
实施例5
归知糖疽有效成分配方颗粒治疗糖尿病肾病的试验研究
1、临床资料
80例均为2021年1月—2023年2月期间收集的DN患者(肝肾亏虚、瘀血湿浊型)。中医证候诊断标准参照《中药新药临床研究指导原则》，辨证分型标准参照《糖尿病肾病诊断、辨证分型及疗效评定标准(试行方案)》。DM诊断标准参照1999年WHO糖尿病研究组提出的糖尿病诊断标准制定。80例患者随机分为治疗组和对照组，治疗组40例，对照组40例。治疗前2组患者性别、年龄、糖尿病病程、糖尿病肾病病程构成等比较，差异无统计学意义(P＞0.05)，说明2组患者具有可比性。
2、治疗方法
2组患者均采用基础治疗。治疗组在基础治疗的同时加用归知糖疽有效成分配方颗粒，每次1g，3次/日口服；对照组在上述基础治疗的同时加用盐酸贝那普利片(洛汀新，北京诺华制药有限公司生产，国药准字H20030514)10mg，1次/日，口服。2个月为1个疗程，共观察1个疗程。
（1）观察指标
分别于治疗前后检测空腹血糖(FBG)、餐后2h血糖(2hPG)、糖化血红蛋白(HbA1c)，24hUpro、UAER。
（2）疗效判定
疗效评价标准参照《中药新药临床研究指导原则》进行评价。
（3）统计方法
采用SPSS17.0统计软件处理。常规进行方差齐性检验及正态检验，计量资料以表示，计量资料比较采用t检验，2组有效率比较采用卡方检验，检验统计学意义设为P＜0.05。
3、治疗结果
（1）治疗后两组综合疗效比较
两组综合疗效比较，治疗组显著优于对照组，见表4。
表4治疗后两组综合疗效比较
注:组间比较，##P＜0.05。
（2）治疗前后两组FBG、2hPG、HbA1c疗效比较
治疗后两组FBG、2hPG、HbA1c均较治疗前变化明显，治疗组优于对照组，见表5。
表5治疗前后两组FBG、2hPG、HbA1c疗效比较
注:与治疗前比较，##P＜0.05。
（3）治疗前后两组24hUpro、UAER疗效比较
治疗前后24hUpro、UAER均有变化，治疗组优于对照组，见表6。
表6治疗前后两组24hUpro、UAER疗效比较
注:与治疗前比较，##P＜0.05；与对照组治疗后比较，△P＜0.05。
研究结果表明，归知糖疽有效成分配方颗粒能明显改善DN患者的临床症状，降低24hUpro、UAER，作用明显优于对照药品洛汀新。
实验例6
典型病例：
李XX，男，62岁，既往高血压病10多年，血压最高达230/100mmHg，糖尿病史10年，间断性水肿5年，全身乏力1个月，腹胀，恶心呕吐，尿量减少（每日约500~800ml），尿液泡沫增多，于当地乡医院住院10天，治疗效果差，随后就诊于省级医院治疗疗效不明显，检查：尿PRO++，24小时尿蛋白定量15.18g/24小时，尿素氮11.9mmoL/L，肌酐342umoL/L。2022年9月21日开始口服归知糖疽有效成分配方颗粒，每次1g，3次/日，60天后，化验结果示：尿PRO+，血压值趋于正常，全身水肿及全身乏力症状消失，精神、食欲、睡眠均可，血肌酐135.5μmol/L，尿素氮7.2mmol/L，空腹血糖5.6mmol/L，餐后2小时血糖7.8mmol/L，病情稳定出院。
刘XX，女，51岁，曾患糖尿病11年，2010年11月开始注射胰岛素，每天56单位，此时尿蛋白已出现3年，一般++～+++，肾脏功能中度受损，治疗前尿素氮达12.68mmol/L，肌酐312μmol/L。此外患者糖尿病典型症状严重，“三多一少”明显，精神萎靡不振。2022年7月开始归知糖疽有效成分配方颗粒，每次1g，3次/日，60天后，尿素氮8.9mmol/L，肌酐230μmol/L，治疗6个月后化验，尿素氮5.07mmol/L，肌酐130μmol/L。糖尿病症状基本消失，精神好转。
Claims (5)
1.一种归知糖疽有效成分配方在制备治疗糖尿病肾病药物中的应用，其特征在于：所述归知糖疽有效成分配方由以下成分组成：藁本内酯、β-谷甾醇、花旗松素、木犀草素、小檗碱、甘草查耳酮A、柳杉酚、知母皂苷B-II、芒果苷、獐牙菜苷、金丝桃苷、梓醇、桃叶珊瑚苷、玄参苷；
所述各个成分的质量比为藁本内酯∶β-谷甾醇∶花旗松素∶木犀草素∶小檗碱∶甘草查耳酮A∶柳杉酚∶知母皂苷B-II∶芒果苷∶獐牙菜苷∶金丝桃苷∶梓醇∶桃叶珊瑚苷∶玄参苷为2.75∶3.4∶4.95∶2.5∶2.1∶1.25∶3.05∶3.65∶4.2∶1.25∶3.0∶0.75∶1.65∶1.8。
2.根据权利要求1所述的归知糖疽有效成分配方在制备治疗糖尿病肾病药物中的应用，其特征在于：所述归知糖疽有效成分配方能明显减少糖尿病肾病大鼠24h尿蛋白含量，降低血尿素氮BUN、血清肌酐Scr、甘油三酯TG含量，提高一氧化氮NO的含量，改善肾功能。
3.根据权利要求1所述的归知糖疽有效成分配方在制备治疗糖尿病肾病药物中的应用，其特征在于：所述归知糖疽有效成分配方可以减少肾组织中TGF-β1蛋白表达，增加Smad7蛋白表达。
4.根据权利要求1所述的归知糖疽有效成分配方在制备治疗糖尿病肾病药物中的应用，其特征在于：所述归知糖疽有效成分配方能明显降低UAER、空腹血糖FBG、餐后2h血糖2hPG、糖化血红蛋白HbA1c。
5.一种治疗糖尿病肾病的药物，其特征在于：所述药物包括归知糖疽有效成分配方，所述有效成分配方由以下成分组成：藁本内酯、β-谷甾醇、花旗松素、木犀草素、小檗碱、甘草查耳酮A、柳杉酚、知母皂苷B-II、芒果苷、獐牙菜苷、金丝桃苷、梓醇、桃叶珊瑚苷、玄参苷，所述各个成分的质量比为藁本内酯∶β-谷甾醇∶花旗松素∶木犀草素∶小檗碱∶甘草查耳酮A∶柳杉酚∶知母皂苷B-II∶芒果苷∶獐牙菜苷∶金丝桃苷∶梓醇∶桃叶珊瑚苷∶玄参苷为2.75∶3.4∶4.95∶2.5∶2.1∶1.25∶3.05∶3.65∶4.2∶1.25∶3.0∶0.75∶1.65∶1.8。
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202311623283.0A CN117298132B (zh) | 2023-11-30 | 2023-11-30 | 一种归知糖疽有效成分配方在制备治疗糖尿病肾病药物中的应用 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202311623283.0A CN117298132B (zh) | 2023-11-30 | 2023-11-30 | 一种归知糖疽有效成分配方在制备治疗糖尿病肾病药物中的应用 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN117298132A CN117298132A (zh) | 2023-12-29 |
| CN117298132B true CN117298132B (zh) | 2024-02-23 |
Family
ID=89287049
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202311623283.0A Active CN117298132B (zh) | 2023-11-30 | 2023-11-30 | 一种归知糖疽有效成分配方在制备治疗糖尿病肾病药物中的应用 |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN117298132B (zh) |
Citations (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101032591A (zh) * | 2007-04-09 | 2007-09-12 | 唐贝宁医药科技（北京）有限公司 | 一种新型纯中药制剂的配方 |
| CN101032592A (zh) * | 2007-04-09 | 2007-09-12 | 唐贝宁医药科技（北京）有限公司 | 一种新型纯中药制剂的配方及其制备方法 |
| CN101675970A (zh) * | 2008-09-16 | 2010-03-24 | 倪海军 | 一种治疗糖尿病的纯中药制剂 |
| CN101683453A (zh) * | 2008-09-28 | 2010-03-31 | 刘显富 | 一种中药制剂的配方 |
| CN107158016A (zh) * | 2017-06-09 | 2017-09-15 | 徐州医科大学 | 知母皂苷及其苷元在制备预防与治疗早期糖尿病肾病药物中的应用 |
| CN110917296A (zh) * | 2019-12-03 | 2020-03-27 | 江苏康缘药业股份有限公司 | 一种中药组合物在制备用于糖尿病肾病药物中的应用 |
| KR20220081419A (ko) * | 2020-12-08 | 2022-06-16 | 대한민국(농촌진흥청장) | 발효 당귀 추출물을 유효성분으로 함유하는 당뇨병성 신증 예방 또는 치료용 조성물 및 이의 제조방법 |
| CN116808147A (zh) * | 2023-07-07 | 2023-09-29 | 江苏省中医院 | 一种治疗糖尿病肾病的中药复方组合物及其质量检测方法 |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101921270A (zh) * | 2009-06-16 | 2010-12-22 | 海南德泽药物研究有限公司 | 一种芒果苷小檗碱盐及其制备方法与用途 |
-
2023
- 2023-11-30 CN CN202311623283.0A patent/CN117298132B/zh active Active
Patent Citations (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101032591A (zh) * | 2007-04-09 | 2007-09-12 | 唐贝宁医药科技（北京）有限公司 | 一种新型纯中药制剂的配方 |
| CN101032592A (zh) * | 2007-04-09 | 2007-09-12 | 唐贝宁医药科技（北京）有限公司 | 一种新型纯中药制剂的配方及其制备方法 |
| CN101675970A (zh) * | 2008-09-16 | 2010-03-24 | 倪海军 | 一种治疗糖尿病的纯中药制剂 |
| CN101683453A (zh) * | 2008-09-28 | 2010-03-31 | 刘显富 | 一种中药制剂的配方 |
| CN107158016A (zh) * | 2017-06-09 | 2017-09-15 | 徐州医科大学 | 知母皂苷及其苷元在制备预防与治疗早期糖尿病肾病药物中的应用 |
| CN110917296A (zh) * | 2019-12-03 | 2020-03-27 | 江苏康缘药业股份有限公司 | 一种中药组合物在制备用于糖尿病肾病药物中的应用 |
| KR20220081419A (ko) * | 2020-12-08 | 2022-06-16 | 대한민국(농촌진흥청장) | 발효 당귀 추출물을 유효성분으로 함유하는 당뇨병성 신증 예방 또는 치료용 조성물 및 이의 제조방법 |
| CN116808147A (zh) * | 2023-07-07 | 2023-09-29 | 江苏省中医院 | 一种治疗糖尿病肾病的中药复方组合物及其质量检测方法 |
Non-Patent Citations (10)
| Title |
|---|
| 小檗碱对早期糖尿病肾病大鼠肾组织TGF-β1/SnoN表达失衡及其Smad信号通路的调控作用;刘圣;余娜;张小力;陈象青;唐丽琴;;中国中药杂志(23);3604-3610 * |
| 归知糖疽颗粒对I型糖尿病大鼠周围神经和外周血管病变及形态学的影响;洪晓华等;《中国中药杂志》;3126-3129 * |
| 朝医学对糖尿病肾病的防治;朴仁范;;中国民族医药杂志(05);全文 * |
| 木犀草素对STZ诱导的糖尿病肾脏的保护作用;张翠;王国光;朱海龙;陆晓华;张根葆;;中国病理生理杂志(12);全文 * |
| 环烯醚萜类化合物在防治糖尿病方面研究进展;杨春辉;马莉;魏振平;;化学工业与工程(06);全文 * |
| 芒果苷在植物界的分布及药理活性研究进展;孙晨瑜;谢国勇;秦民坚;;中国野生植物资源(04);全文 * |
| 芒果苷改善代谢性疾病药理作用研究进展;马燕敏;刘梦扬;陈倩;王涛;;长春中医药大学学报(03);606-609 * |
| 花旗松素对糖尿病肾病大鼠的作用及机制分析;吴奋飞等;《解放军药学学报》;514-520 * |
| 金丝桃苷对糖尿病肾病大鼠TGF-β1/smad通路及肾上皮间质转化的影响;王苑菲等;《广西医科大学学报》;1654-1660 * |
| 黄连素(小檗碱)治疗糖尿病肾病疗效和安全性的系统评价;姚金铭;宋秀玲;王焕君;赵军玉;尚红霞;冷玲;廖琳;董建军;;中华临床医师杂志(电子版)(23);全文 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN117298132A (zh) | 2023-12-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101313942B (zh) | 一种治疗肾病的中药组合物 | |
| CN101642529B (zh) | 一种能治疗糖尿病的制剂 | |
| CN102397372A (zh) | 一种药物组合物及制剂和其在治疗肠易激综合征中的应用 | |
| CN104645132A (zh) | 一种治疗糖尿病肾病的中药组合物、制备方法、中药制剂及应用 | |
| CN101524494A (zh) | 一种治疗痛风的药物 | |
| CN102641430B (zh) | 一种治疗糖尿病肾病的中药汤剂 | |
| CN103006989B (zh) | 一种治疗糖尿病肾病的药物组合物 | |
| CN117298132B (zh) | 一种归知糖疽有效成分配方在制备治疗糖尿病肾病药物中的应用 | |
| CN102018852B (zh) | 参连消渴降糖胶囊及制作工艺 | |
| CN1329067C (zh) | 治疗糖尿病的中药制剂 | |
| CN102813807B (zh) | 肾阴亏损型糖尿病用的中药汤剂 | |
| CN103690768A (zh) | 麦冬参芪软胶囊及其制备方法 | |
| CN103638389A (zh) | 一种治疗糖尿病的中药组合物 | |
| CN103585495B (zh) | 一种治疗糖尿病肾损害的胶囊 | |
| CN101612273B (zh) | 一种用于治疗半身不遂及脑血栓的药物组合物 | |
| CN100536899C (zh) | 一种预防和治疗早期糖尿病肾病的中药 | |
| CN101269187A (zh) | 一种治疗膀胱癌的药物组合及其制备方法 | |
| CN101199687A (zh) | 一种治疗慢性前列腺炎的药物组合物及其制备方法 | |
| CN103656516A (zh) | 一种治疗糖尿病肾病的中药制剂 | |
| CN117379505B (zh) | 一种治疗慢性肾脏病的中药组合物 | |
| CN103520538B (zh) | 一种治疗糖尿病引致肾脏损害的药物组合物 | |
| CN103877374B (zh) | 一种用于治疗糖尿病的中药及其制备方法 | |
| CN116098958B (zh) | 一种治疗气阴两虚兼血瘀型早期糖尿病肾病的中药组合物及其制备方法 | |
| CN102247515A (zh) | 治疗糖尿病肾病的中药复方制剂及其制备方法 | |
| CN100525822C (zh) | 治疗糖尿病肾病的胶囊 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |